Inquis Medical
Inquis Medical develops the AVENTUS Thrombectomy System, an integrated single-catheter mechanical thrombectomy platform with proprietary TrueClot tissue-sensing and autologous blood reinfusion, sold to U.S. hospitals and interventional cardiologists and radiologists for treatment of pulmonary embolism and venous thromboembolism.
- Company typePrivate
- Founded2020
- HeadquartersMenlo Park, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Inquis Medical does
Inquis Medical is a privately held medical device company founded in 2020 and headquartered in Menlo Park, California, focused on mechanical thrombectomy for venous thromboembolic disease, with an initial emphasis on pulmonary embolism (PE). The company has developed the AVENTUS Precision Thrombectomy System, an integrated single-catheter platform that combines directional aspiration with a proprietary TrueClot tissue-sensing capability designed to differentiate blood, clot, and vessel wall in real time during aspiration. The platform also incorporates an in-line AVENTUS Clot Management System that filters and reinfuses aspirated blood to minimize blood loss, and a complementary AVENTUS Introducer Sheath with adaptive seal technology.
The company sells capital equipment and associated consumables directly to U.S. hospitals and academic medical centers, targeting interventional cardiologists, interventional radiologists, and vascular surgeons who treat PE and deep vein thrombosis. Following FDA 510(k) clearance for the peripheral indication in 2024 and for pulmonary embolism in June 2025, Inquis Medical transitioned to a commercial-stage organization and launched national rollout supported by a $75 million Series C financing closed in January 2026. The AVENTUS IDE pivotal trial enrolled 130 patients across 22 U.S. sites and reported zero device-related major adverse events, a 27% reduction in RV/LV ratio, and a 35.9% reduction in clot burden, providing the primary commercial evidence base.
The company's go-to-market is enterprise field sales to hospital systems, complemented by peer-to-peer physician education, presence at interventional cardiology and radiology conferences (including SCAI), and published clinical evidence in JSCAI. Inquis Medical operates in a competitive segment alongside larger incumbents such as Inari Medical, Penumbra, and BD Peripheral Intervention, and competes on the basis of an integrated system that eliminates multiple catheter exchanges, reduces blood loss to under 50 mL on average, and removes the need for capital equipment outlays. As of early 2026 the company had raised approximately $115 million in total equity financing and was actively scaling its sales force and physician-training infrastructure.
Inquis Medical firmographics
Firmographics- Name
- Inquis Medical
- Legal name
- Inquis Medical, Inc.
- Website
- https://inquismedical.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Inquis Medical develops the AVENTUS Thrombectomy System, an integrated single-catheter mechanical thrombectomy platform with proprietary TrueClot tissue-sensing and autologous blood reinfusion, sold to U.S. hospitals and interventional cardiologists and radiologists for treatment of pulmonary embolism and venous thromboembolism.
- Ownership category
- akta.pro rank
Inquis Medical industry classification
Industry- Product category
- Mechanical Thrombectomy Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro industry
- Thrombectomy, Embolic Protection & Stroke Intervention DevicesHealthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
Keywords
Where Inquis Medical is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Inquis Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- AVENTUS Thrombectomy System Sales: Revenue is generated through the sale of the AVENTUS Thrombectomy System and related consumables (introducer sheaths, blood filtration components) to hospitals and healthcare providers. The system is sold as a capital device with associated procedural consumables.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Inquis Medical product offering
Product offeringCore offering
Inquis Medical develops and commercializes the AVENTUS Thrombectomy System, a next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). The system combines a 24-F aspiration catheter with proprietary TrueClot tissue-sensing technology, integrated directional aspiration, and the AVENTUS Clot Management System for autologous blood reinfusion. The company sells the device and associated consumables (introducer sheaths, blood filtration components) to U.S. hospitals and interventional physicians.
Product overview
Inquis Medical offers the AVENTUS Precision Thrombectomy System as its core product platform for treating venous thromboembolic disease. The system consists of the AVENTUS Thrombectomy System (main aspiration catheter with TrueClot™ sensing technology), the AVENTUS Clot Management System (blood filtration and reinfusion module), and the AVENTUS Introducer Sheath (access device with adaptive seal). These products work together as an integrated platform enabling precision clot removal with real-time tissue sensing and autologous blood reinfusion for pulmonary embolism and peripheral vascular procedures.
Differentiator
Problem solved
Functional benefit
Brands
- AVENTUS Thrombectomy System: Next-generation mechanical thrombectomy platform with proprietary TrueClot tissue-sensing technology for treatment of pulmonary embolism and peripheral vascular conditions.
Products and services
- AVENTUS Thrombectomy System Next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). Features proprietary TrueClot tissue-sensing technology for real-time differentiation between blood, clot, and vessel wall, integrated directional aspiration, and 24-F catheter design with no capital equipment required. Sold to U.S. hospitals and interventional cardiologists/radiologists.
- AVENTUS Clot Management System Blood filtration and reinfusion system used with the AVENTUS Thrombectomy System to enable autologous blood transfusion. Filters aspirated blood and returns it to the patient without syringe disconnection, reducing blood loss to under 50 mL mean per patient and eliminating transfusion requirements.
- AVENTUS Introducer Sheath Introducer sheath with adaptive seal technology featuring single-handed control using one button and an iris valve that delivers consistent sealing across all device sizes. Compatible with the AVENTUS Thrombectomy System for smooth and effortless device advancement during PE and peripheral vascular procedures.
Quantifiable outcome
- Zero device-related major adverse events (MAEs) within 48 hours and through 30 days across 130 patients in pivotal trial
- +5 more outcomes
Companies that use Inquis Medical
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Inquis Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Inquis Medical partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Inquis Medical competitors and assessment
Company assessmentBroad incumbents
- Merit Medical Systems: Merit Medical offers a portfolio of vascular intervention, drainage, and thrombectomy-related devices sold to interventional radiology and cardiology customers, making it a broad incumbent competing for hospital share of wallet.
- Becton Dickinson (BD): BD's Peripheral Intervention business includes the Rotarex rotational thrombectomy catheter and broader venous/vascular portfolio. Inquis's CCO Matt Fermanich previously led BD Peripheral Intervention, illustrating direct competitive overlap and incumbency.
- Boston Scientific: Boston Scientific is a broad interventional medtech incumbent with a peripheral intervention portfolio (including AngioJet and acquired Devoro Medical rotational thrombectomy assets) and large hospital sales force targeting the same interventional cardiology and radiology accounts.
- Teleflex: Teleflex offers interventional vascular access and thrombectomy-adjacent products to the same hospital-based interventionalists; a broad incumbent whose portfolio competes for the same procedural budgets.
- Johnson & Johnson (Biosense Webster / J&J MedTech): J&J markets the AngioVac venous thrombectomy system and a broad interventional cardiology/radiology portfolio, serving the same hospital accounts and competing in PE and venous thromboembolism.
Others
- Stryker: Stryker acquired Inquis co-founder Vahid Saadat's prior company Arrinex, demonstrating a known acquisition appetite in medtech. While Stryker's current portfolio is not a direct PE thrombectomy competitor, it represents a credible strategic acquirer for Inquis.
- Edwards Lifesciences: Edwards Lifesciences is a major cardiovascular medtech incumbent serving interventional cardiology and cardiac surgery customers; not a direct thrombectomy competitor but a comparable cardiovascular hospital-channel peer and potential strategic acquirer.
Direct peers
- Penumbra: Penumbra's Indigo aspiration system with Lightning intelligent aspiration is a leading catheter-based thrombectomy platform for PE and venous thromboembolism, directly overlapping with AVENTUS in indication, mechanism, and customer base.
- Inari Medical: Inari Medical's FlowTriever and ClotTriever systems are the leading mechanical thrombectomy platforms for pulmonary embolism and DVT — the most direct competitor to AVENTUS in target indication, customer (interventional cardiology/radiology), and procedural use case.
- AngioDynamics: AngioDynamics markets the alphaVac system for mechanical thrombectomy in PE, directly competing with AVENTUS in indication, mechanism of action, and target hospital accounts for venous thromboembolism.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Inquis Medical social profiles
Digital presenceInquis Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inquis Medical leadership team
Management profileNumber of profiles
Profiles16 records
Inquis Medical funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inquis Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inquis Medical
What does Inquis Medical do?
Inquis Medical develops and commercializes the AVENTUS Thrombectomy System, a next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). The system combines a 24-F aspiration catheter with proprietary TrueClot tissue-sensing technology, integrated directional aspiration, and the AVENTUS Clot Management System for autologous blood reinfusion. The company sells the device and associated consumables (introducer sheaths, blood filtration components) to U.S. hospitals and interventional physicians.
Is Inquis Medical a public or private company?
Inquis Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inquis Medical founded?
Inquis Medical was founded in 2020. It employs 51 to 100 people.
Where is Inquis Medical based?
Inquis Medical is headquartered in Menlo Park, United States, in the North America region.
How does Inquis Medical make money?
One revenue line is on record: AVENTUS Thrombectomy System Sales.
Who are Inquis Medical's main competitors?
Broad incumbents on record are Merit Medical Systems, Becton Dickinson (BD), Boston Scientific, Teleflex and Johnson & Johnson (Biosense Webster / J&J MedTech). Others are Stryker and Edwards Lifesciences. Direct peers are Penumbra, Inari Medical and AngioDynamics.
Does Inquis Medical have an API?
No public API is recorded for Inquis Medical.
What industry is Inquis Medical in?
Inquis Medical's product category is Mechanical Thrombectomy Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.